Market/Novel Tech Articles
Novartis AG (NYSE: NVS; SIX: NOVN) sees the addition of virtual technology to clinical trials as a significant component for future drug development and surveillance.
Novartis AG (NYSE: NVS; SIX: NOVN) has recently launched a new app, “FocalView”, aiming to provide “an opportunity for patients to participate in ophthalmology clinical trials from home”. According to the company, the new initiative is the “first-of-its-kind app” to make ophthalmic clinical trials more accessible and flexible. The app will capture patients’ self-recorded measurements […]Read full story
Dutch company ProQR Therapeutics N.V. (NASDAQ: PRQR) and US Foundation Fighting Blindness enter a collaborative partnership to develop a treatment for Usher syndrome
ProQR Therapeutics N.V. (NASDAQ: PRQR) and the US charity Foundation Fighting Blindness (FFB) have announced a new partnership to accelerate the development of a novel therapeutic, “QR-421a”, for the treatment of Usher syndrome 2A. The sensorineural disease, which affects approximately 16,000 patients worldwide, is caused by a mutation in exon 13 of the causative USH2A […]Read full story
Topline data from GenSight’s Phase III REVERSE study provide an unusual and unexpected outcome
GenSight Biologics S.A. (Euronext: SIGHT) has announced topline results from the company’s Phase III “REVERSE” clinical study of an experimental gene therapy, ”GS010”, designed for the treatment of Leber Hereditary Optic Neuropathy (LHON). According to the company, the study evaluated the safety and efficacy of a single intravitreal injection of GS010 (rAAV2/2-ND4) in 37 […]Read full story